Stockscreener 앱 받기
3.02
3.07%
0.09
시간 외 거래:
3.00
-0.02
-0.66%
전일 마감가:
$2.93
열려 있는:
$3
하루 거래량:
4.56M
Relative Volume:
3.52
시가총액:
$489.08M
수익:
-
순이익/손실:
$-274.18M
주가수익비율:
-1.1915
EPS:
-2.5346
순현금흐름:
$-198.33M
1주 성능:
+14.83%
1개월 성능:
+65.93%
6개월 성능:
+287.28%
1년 성능:
-73.62%
1일 변동 폭
$2.82
$3.25
1주일 범위
$2.40
$3.25
52주 변동 폭
$0.611
$14.09
Neumora Therapeutics Inc Stock (NMRA) Company Profile
명칭
Neumora Therapeutics Inc
전화
(857) 760-0900
주소
260 ARSENAL PLACE, SUITE 1, WATERTOWN
NMRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
3.02 | 474.50M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-27 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-09-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-04-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-03-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Hold |
| 2023-10-10 | 개시 | BofA Securities | Buy |
| 2023-10-10 | 개시 | Guggenheim | Buy |
| 2023-10-10 | 개시 | JP Morgan | Overweight |
| 2023-10-10 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-10 | 개시 | Stifel | Buy |
| 2023-10-10 | 개시 | William Blair | Outperform |
모두보기
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
What risks investors should watch in Neumora Therapeutics Inc. stockQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
Will Neumora Therapeutics’ (NMRA) Novel Drug Pipeline Define Its Competitive Edge in Biotech? - simplywall.st
What momentum shifts mean for Neumora Therapeutics Inc.July 2025 WrapUp & Expert Curated Trade Setup Alerts - newser.com
Is Neumora Therapeutics Inc. stock entering bullish territory2025 Market Sentiment & Reliable Price Action Trade Plans - newser.com
Regression analysis insights on Neumora Therapeutics Inc. performance2025 Year in Review & Daily Profit Maximizing Tips - newser.com
Heatmap analysis for Neumora Therapeutics Inc. and competitors2025 Dividend Review & Free High Accuracy Swing Entry Alerts - newser.com
Why Neumora Therapeutics Inc. stock is a must watch in 2025July 2025 WrapUp & Low Volatility Stock Suggestions - newser.com
Neumora Therapeutics Inc. stock outlook for YEARJuly 2025 Review & Free Safe Capital Growth Stock Tips - newser.com
Published on: 2025-10-31 04:44:03 - newser.com
Published on: 2025-10-31 03:53:08 - newser.com
How moving averages guide Neumora Therapeutics Inc. trading2025 Sector Review & Low Risk High Win Rate Picks - newser.com
Neumora Therapeutics (NMRA): Evaluating Valuation Following Dual Pipeline Advances in Psychiatry and Obesity - Yahoo Finance
Can a trend reversal in Neumora Therapeutics Inc. lead to recoveryExit Point & AI Driven Price Predictions - newser.com
Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating - Insider Monkey
Arch Venture Partners Xii, Llc Acquires 1,915,700 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Director Kristina Burow Acquires 1,915,700 Shares - MarketBeat
Is Neumora Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 News Drivers & AI Powered Market Entry Ideas - newser.com
Neumora Therapeutics Stock (NMRA) Opinions on Obesity Drug Data Release - Quiver Quantitative
Guggenheim upgrades Neumora Therapeutics, Inc. (NMRA) to a Buy - The Globe and Mail
Neumora to initiate phase 1 study of oral obesity pill - MSN
Published on: 2025-10-30 01:21:45 - newser.com
Major Stakeholders Make Bold Moves in Neumora Therapeutics! - TipRanks
Neumora Therapeutics (NASDAQ:NMRA) Price Target Raised to $8.00 - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Is Neumora Therapeutics Inc. stock a top pick in earnings season2025 Buyback Activity & Safe Entry Zone Tips - Fundação Cultural do Pará
14 Stocks Under $5 with Highest Upside Potential - Insider Monkey
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $5 to $18 - 富途牛牛
Needham Maintains Neumora Therapeutics (NMRA) Buy Recommendation - Nasdaq
Why hedge funds are buying Neumora Therapeutics Inc. stock2025 Market Trends & Weekly Top Gainers Alerts - Fundação Cultural do Pará
Real time social sentiment graph for Neumora Therapeutics Inc.2025 Top Gainers & Verified Entry Point Signals - newser.com
Published on: 2025-10-30 01:45:00 - newser.com
Will Neumora Therapeutics Inc. stock reach Wall Street targetsEarnings Recap Summary & Weekly Hot Stock Watchlists - Fundação Cultural do Pará
Neumora initiates phase 1 study of second M4 PAM compound By Investing.com - Investing.com Philippines
How Neumora Therapeutics Inc. stock valuations compare to rivalsPortfolio Return Report & Free Safe Entry Trade Signal Reports - Fundação Cultural do Pará
Neumora’s obesity drug shows up to 26% weight loss in preclinical studies - Investing.com Canada
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Breakthrough for Major Depressive Disorder - TipRanks
Neumora Therapeutics’ NMRA-323511 Study: A Potential Breakthrough in Alzheimer’s Treatment - TipRanks
Neumora initiates phase 1 study of second M4 PAM compound - Investing.com
How Neumora Therapeutics Inc. stock performs after earnings2025 Key Highlights & Free Community Consensus Stock Picks - Fundação Cultural do Pará
Is Neumora Therapeutics Inc. stock positioned well for digital economyJuly 2025 Movers & Low Risk High Reward Trade Ideas - Fundação Cultural do Pará
Neumora Therapeutics Inc (NMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
0.21%
자본화:
|
볼륨(24시간):